Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: NETHERLANDS

Sector: Biotechnology

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 98 full-time employees. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Website: merus.nl


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-2.2%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 4.0% (LTM)
  • Share price is 427.1% higher than minimum and 0.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $4.6 mln (-0.121% of cap.)

Key Financials (Download financials)

Ticker: MRUS
Share price, USD:  (+1.9%)67.47
year average price 49.59  


year start price 50.00 2024-09-07

min close price 34.89 2025-04-08

max close price 67.49 2025-08-22

current price 67.47 2025-09-07
Common stocks: 68 254 120

Dividend Yield:  0.0%
EV / Sales: 113.1x
Margin (EBITDA LTM / Revenue): -750.0%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4 605
Net Debt ($m): -535
EV (Enterprise Value): 4 070
EBITDA LTM (млн $): -270
Price to Book: 6.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-08-05zacks.com

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

2025-07-11zacks.com

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

2025-06-05youtube.com

Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer

2025-06-04globenewswire.com

Merus N.V. Announces Pricing of Public Offering of Common Shares

2025-05-22globenewswire.com

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

2025-05-07zacks.com

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

2025-04-07seekingalpha.com

Merus: Riding The Bispecific Wave In Oncology

2025-02-27zacks.com

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

2025-01-20seekingalpha.com

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

2024-12-16globenewswire.com

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-31 2024-08-01 2024-05-08 2024-02-28 2023-11-02 2023-08-07 2023-05-04 2023-02-28 2022-11-03 2022-08-08
acceptedDate 2024-10-31 08:00:21 2024-08-01 16:05:29 2024-05-08 16:05:47 2024-02-28 16:05:45 2023-11-02 16:05:34 2023-08-07 16:13:03 2023-05-04 16:06:16 2023-02-28 16:09:13 2022-11-03 07:31:22 2022-08-08 16:08:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 12M 7M 8M 9M 11M 10M 13M 11M 7M 13M
costOfRevenue 0 0 607 000 37M 35M 26M 0 327 000 0 0
grossProfit 12M 7M 7M -28M -24M -15M 13M 10M 7M 0
grossProfitRatio 1 1 0.923 -3.123 -2.156 -1.475 1 0.969 1 0
researchAndDevelopmentExpenses 63M 49M 39M 41M 37M 28M 35M 49M 42M 31M
generalAndAdministrativeExpenses 21M 23M 16M 16M 13M 16M 15M 15M 12M 13M
sellingAndMarketingExpenses 0 -640 000 -607 000 -618 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 21M 22M 16M 15M 13M 16M 15M 15M 12M 13M
otherExpenses 0 0 0 0 0 0 0 0 0 0
operatingExpenses 84M 71M 54M 56M 49M 44M 50M 64M 55M 44M
costAndExpenses 84M 72M 55M 56M 49M 44M 50M 64M 55M 44M
interestIncome 10M 7M 0 5M 5M 3M 0 0 0 0
interestExpense 0 0 0 13M 0 0 2M 1M 866 000 316 000
depreciationAndAmortization 635 000 640 000 607 000 43 812 659 000 675 000 6M 30M -23M 322 000
ebitda -96M -59M -46M -47M -22M -34M -31M -24M -71M -5M
ebitdaratio -8.18 -8.693 -5.857 -5.249 -1.984 -3.223 -2.276 -2.25 -10.779 -0.39
operatingIncome -72M -64M -47M -48M -22M -34M -37M -54M -48M -31M
operatingIncomeRatio -6.136 -8.78 -5.933 -5.318 -1.984 -3.235 -2.723 -5.031 -7.323 -2.452
totalOtherIncomeExpensesNet -25M 12M 13M -12M 12M 551 000 -3M -28M 24M 26M
incomeBeforeTax -97M -48M -33M -59M -22M -31M -40M -82M -24M -6M
incomeBeforeTaxRatio -8.234 -6.509 -4.228 -6.613 -1.984 -2.915 -2.978 -7.649 -3.691 -0.44
incomeTaxExpense 3M 2M 1M 1M 1M 1M -457 000 387 000 327 000 131 000
netIncome -100M -50M -34M -60M -23M -32M -40M -82M -25M -6M
netIncomeRatio -8.487 -6.825 -4.368 -6.729 -2.086 -3.058 -2.944 -7.685 -3.74 -0.45
eps -1.46 -0.81 -0.59 -1.04 -0.43 -0.66 -0.86 -2.12 -0.53 -0.13
epsdiluted -1.46 -0.81 -0.59 -1.04 -0.43 -0.66 -0.86 -2.12 -0.53 -0.13
weightedAverageShsOut 68M 62M 58M 58M 54M 48M 46M 39M 46M 44M
weightedAverageShsOutDil 68M 62M 58M 58M 54M 48M 46M 39M 46M 44M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-31 2024-08-01 2024-05-08 2024-02-28 2023-11-02 2023-08-07 2023-05-04 2023-02-28 2022-11-03 2022-08-08
acceptedDate 2024-10-31 08:00:21 2024-08-01 16:05:29 2024-05-08 16:05:47 2024-02-28 16:05:45 2023-11-02 16:05:34 2023-08-07 16:13:03 2023-05-04 16:06:16 2023-02-28 16:09:13 2022-11-03 07:31:22 2022-08-08 16:08:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 433M 629M 178M 205M 242M 101M 103M 148M 191M 214M
shortTermInvestments 199M 158M 159M 150M 147M 164M 139M 142M 160M 162M
cashAndShortTermInvestments 632M 787M 337M 355M 389M 265M 241M 290M 351M 376M
netReceivables 4M 4M 60M 4M 5M 4M 6M 5M 3M 4M
inventory 0 0 1 1 10M 12M 9M 9M 0 0
otherCurrentAssets 30M 15M 12M 10M 1M 2M 2M 2M 951 000 18M
totalCurrentAssets 666M 807M 410M 369M 405M 283M 258M 306M 368M 399M
propertyPlantEquipmentNet 22M 22M 22M 23M 23M 25M 26M 25M 20M 20M
goodwill 0 0 0 0 0 0 0 0 0 0
intangibleAssets 2M 2M 2M 2M 2M 2M 2M 2M 2M 0
goodwillAndIntangibleAssets 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
longTermInvestments 151M 59M 61M 57M 57M 47M 46M 36M 21M 21M
taxAssets 838 000 543 000 277 000 4M 702 000 3M 2M 2M 435 000 241 000
otherNonCurrentAssets 3M 2M 3M 3M 4M 4M 4M 5M 3M 3M
totalNonCurrentAssets 178M 86M 88M 90M 87M 80M 80M 70M 47M 46M
otherAssets 0 0 0 0 0 0 0 0 0 0
totalAssets 845M 892M 498M 458M 492M 364M 339M 377M 415M 445M
accountPayables 6M 4M 7M 5M 4M 8M 5M 10M 3M 7M
shortTermDebt 4M 3M 2M 2M 2M 2M 2M 2M 2M 1M
taxPayables 5M 2M 2M 2M 137 000 1M 2M 2M 0 0
deferredRevenue 31M 32M 34M 23M 23M 24M 27M 29M 28M 31M
otherCurrentLiabilities 35M 39M 35M 40M 36M 32M 42M 38M 31M 21M
totalCurrentLiabilities 80M 81M 78M 69M 64M 66M 75M 79M 64M 60M
longTermDebt 9M 9M 10M 10M 11M 11M 12M 12M 11M 12M
deferredRevenueNonCurrent 52M 55M 60M 20M 24M 29M 34M 39M 41M 46M
deferredTaxLiabilitiesNonCurrent 0 -9M -10M 3M -11M -11M -12M -12M 0 0
otherNonCurrentLiabilities 0 0 10M 0 11M 11M 12M 12M 19M 0
totalNonCurrentLiabilities 61M 65M 70M 33M 34M 40M 46M 51M 52M 58M
otherLiabilities 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 11M 11M 10M 10M 12M 13M 13M 13M 13M 14M
totalLiabilities 141M 145M 149M 102M 99M 106M 121M 129M 116M 118M
preferredStock 0 0 0 0 0 0 0 0 0 0
commonStock 7M 7M 6M 6M 6M 5M 5M 5M 5M 5M
retainedEarnings -937M -838M -788M -753M -693M -670M -638M -598M -516M -492M
accumulatedOtherComprehensiveIncomeLoss -7M -39M -30M -23M -37M -27M -26M -30M -55M -35M
othertotalStockholdersEquity 1 641M 1 616M 1 161M 1 126M 1 118M 949M 877M 871M 865M 849M
totalStockholdersEquity 703M 747M 349M 356M 393M 257M 218M 247M 299M 327M
totalEquity 703M 747M 349M 356M 393M 257M 218M 247M 299M 327M
totalLiabilitiesAndStockholdersEquity 845M 892M 498M 458M 492M 364M 339M 377M 415M 445M
minorityInterest 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 845M 892M 498M 458M 492M 364M 339M 377M 415M 445M
totalInvestments 350M 217M 220M 207M 147M 164M 139M 179M 182M 183M
totalDebt 2M 11M 12M 12M 12M 13M 13M 13M 13M 14M
netDebt -431M -618M -167M -193M -230M -88M -89M -134M -178M -200M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS MRUS
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-31 2024-08-01 2024-05-08 2024-02-28 2023-11-02 2023-08-07 2023-05-04 2023-02-28 2022-11-03 2022-08-08
acceptedDate 2024-10-31 08:00:21 2024-08-01 16:05:29 2024-05-08 16:05:47 2024-02-28 16:05:45 2023-11-02 16:05:34 2023-08-07 16:13:03 2023-05-04 16:06:16 2023-02-28 16:09:13 2022-11-03 07:31:22 2022-08-08 16:08:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -100M -50M -34M -60M -23M -32M -40M -82M -25M -6M
depreciationAndAmortization 635 000 640 000 607 000 618 000 659 000 675 000 588 000 312 000 300 000 322 000
deferredIncomeTax -287 581 -268 625 923 000 -511 449 2M -687 000 -328 000 -2M -195 000 -161 000
stockBasedCompensation 13M 12M 5M 7M 7M 6M 6M 6M 7M 7M
changeInWorkingCapital -23M 52M -6M 966 289 -3M -15M -8M 2M -4M 9M
accountsReceivables 792 572 57M -57M 1M -681 000 2M -631 000 -1M 1M -2M
inventory 0 0 0 6M 6M -12M 0 0 0 0
accountsPayables 2M -3M 3M 601 856 -4M 3M -3M 5M -3M 2M
otherWorkingCapital -25M -2M 47M -746 424 -5M -8M -4M -2M -2M -9M
otherNonCashItems 29M -49M 50M 17M -11M -833 000 5M 44M -19M 0
netCashProvidedByOperatingActivities -80M 6M -44M -35M -28M -42M -37M -31M -41M -32M
investmentsInPropertyPlantAndEquipment -114 152 -1M -63 000 73 937 -39 000 -349 000 -4M -2M -2M -3M
acquisitionsNet 0 0 0 -19M -8M 22M 0 52 000 0 0
purchasesOfInvestments -197M -40M -59M -29M -60M -79M -65M -49M -51M -65M
salesMaturitiesOfInvestments 63M 45M 47M 27M 68M 55M 60M 52M 52M 72M
otherInvestingActivites -162 999 0 -11M 1 8M -22M 0 -52 000 0 0
netCashUsedForInvestingActivites -134M 3M -12M -2M 8M -25M -8M 856 000 -1M 4M
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued -38M 435M 30M -1M 162M 67M 0 -1000 10M 48M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 11M 10M 30M 3324 253 000 -552 478 217 000 -214 000 150 000 184 000
netCashUsedProvidedByFinancingActivities 11M 443M 30M -1M 162M 66M 217 000 -215 000 10M 48M
effectOfForexChangesOnCash 7M -2M 222 000 -636 000 -2M -1M -171 000 -14M 10M -799 000
netChangeInCash -196M 451M -27M -37M 141M -1M -45M -44M -22M 20M
cashAtEndOfPeriod 434M 629M 178M 205M 243M 102M 103M 148M 192M 215M
cashAtBeginningOfPeriod 629M 178M 205M 242M 102M 103M 148M 192M 215M 195M
operatingCashFlow -81M 6M -44M -35M -28M -42M -37M -31M -41M -32M
capitalExpenditure -114 152 -1M -63 000 73 937 -39 000 -349 000 -4M -2M -2M -3M
freeCashFlow -81M 4M -44M -35M -28M -42M -40M -33M -44M -35M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-10-31 12:08 ET
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
2024-10-31 12:08 ET
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
2024-09-30 12:00 ET
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
2024-09-30 12:00 ET
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
2024-09-17 13:00 ET
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
2024-09-17 13:00 ET
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
2024-08-06 12:00 ET
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
2024-08-06 12:00 ET
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
2024-08-01 20:10 ET
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
2024-08-01 20:10 ET
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
2024-07-24 11:00 ET
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
2024-07-24 11:00 ET
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
2024-07-08 12:00 ET
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
2024-07-08 12:00 ET
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
2024-07-01 12:00 ET
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
2024-07-01 12:00 ET
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
2024-06-03 18:30 ET
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
2024-06-03 18:30 ET
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
2024-06-02 16:30 ET
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
2024-06-02 16:30 ET
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
2024-05-30 01:30 ET
Merus Announces Pricing of Upsized Public Offering of Common Shares
2024-05-30 01:30 ET
Merus Announces Pricing of Upsized Public Offering of Common Shares
2024-05-29 12:00 ET
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
2024-05-29 12:00 ET
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
2024-05-28 20:01 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2024-05-28 20:01 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2024-05-28 11:00 ET
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
2024-05-28 11:00 ET
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
2024-05-23 21:00 ET
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
2024-05-23 21:00 ET
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
2024-05-23 21:00 ET
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
2024-05-23 21:00 ET
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
2024-05-13 12:00 ET
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
2024-05-13 12:00 ET
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
2024-05-08 20:15 ET
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
2024-05-08 20:15 ET
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
2024-05-06 20:05 ET
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
2024-05-06 20:05 ET
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
2024-04-24 14:00 ET
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
2024-04-24 14:00 ET
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
2024-04-08 16:00 ET
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
2024-04-08 16:00 ET
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
2024-04-03 12:00 ET
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
2024-04-03 12:00 ET
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-05 21:30 ET
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
2024-03-05 21:30 ET
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
2024-03-04 13:00 ET
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
2024-03-04 13:00 ET
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
2024-02-28 21:15 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
2024-02-28 21:15 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
2024-01-31 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2024-01-31 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2023-12-03 01:40 ET
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
2023-12-03 01:40 ET
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
2023-11-26 16:05 ET
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
2023-11-26 16:05 ET
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
2023-11-02 20:12 ET
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
2023-11-02 20:12 ET
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
2023-11-01 12:00 ET
Merus to Participate in Upcoming Investor Conferences
2023-11-01 12:00 ET
Merus to Participate in Upcoming Investor Conferences
2023-10-23 11:30 ET
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
2023-10-23 11:30 ET
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
2023-10-15 23:58 ET
Merus Announces Business Update Conference Call
2023-10-15 23:58 ET
Merus Announces Business Update Conference Call
2023-10-06 13:32 ET
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
2023-10-06 13:32 ET
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
2023-08-31 12:00 ET
Merus to Participate in Upcoming Investor Conferences
2023-08-31 12:00 ET
Merus to Participate in Upcoming Investor Conferences
2023-08-10 01:53 ET
Merus Announces Pricing of Public Offering of Common Shares
2023-08-10 01:53 ET
Merus Announces Pricing of Public Offering of Common Shares
2023-08-09 20:01 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2023-08-09 20:01 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2023-08-07 20:26 ET
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
2023-08-07 20:26 ET
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
2023-07-28 12:00 ET
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
2023-07-28 12:00 ET
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
2023-07-05 20:01 ET
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
2023-07-05 20:01 ET
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
2023-06-29 20:30 ET
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
2023-06-29 20:30 ET
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
2023-06-15 11:47 ET
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
2023-06-15 11:47 ET
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
2023-05-31 12:00 ET
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
2023-05-31 12:00 ET
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
2023-05-04 20:25 ET
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
2023-05-04 20:25 ET
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
2023-04-17 14:15 ET
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
2023-04-17 14:15 ET
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
2023-04-14 15:10 ET
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
2023-04-14 15:10 ET
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
2023-04-14 15:10 ET
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
2023-04-14 15:10 ET
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
2023-03-14 20:30 ET
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
2023-03-14 20:30 ET
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
2023-03-14 20:30 ET
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
2023-03-14 20:30 ET
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
2023-02-28 21:25 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
2023-02-28 21:25 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
2023-02-01 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2023-02-01 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2023-01-09 11:05 ET
CORRECTING and REPLACING --Merus Provides 2023 Outlook
2023-01-09 11:05 ET
CORRECTING and REPLACING --Merus Provides 2023 Outlook
2023-01-08 14:00 ET
Merus Provides 2023 Outlook
2023-01-08 14:00 ET
Merus Provides 2023 Outlook
2022-11-09 13:00 ET
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
2022-11-09 13:00 ET
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
2022-11-03 11:51 ET
Merus Announces Financial Results for the Third Quarter and Provides Business Update
2022-11-03 11:51 ET
Merus Announces Financial Results for the Third Quarter and Provides Business Update
2022-10-26 08:00 ET
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
2022-10-26 08:00 ET
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
2022-10-12 11:00 ET
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
2022-10-12 11:00 ET
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
2022-09-07 20:10 ET
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics
2022-09-07 20:10 ET
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics
2022-09-01 12:00 ET
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
2022-09-01 12:00 ET
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
2022-08-08 20:17 ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
2022-08-08 20:17 ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
2022-06-05 15:00 ET
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
2022-06-05 15:00 ET
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
2022-06-03 12:00 ET
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
2022-06-03 12:00 ET
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
2022-05-26 21:00 ET
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-26 21:00 ET
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-17 12:00 ET
Merus to Present at the H.C. Wainwright Global Investment Conference
2022-05-17 12:00 ET
Merus to Present at the H.C. Wainwright Global Investment Conference
2022-05-09 20:29 ET
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
2022-05-09 20:29 ET
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
2022-04-27 20:01 ET
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
2022-04-27 20:01 ET
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
2022-04-25 12:00 ET
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
2022-04-25 12:00 ET
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
2022-04-08 17:00 ET
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
2022-04-08 17:00 ET
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
2022-04-06 12:00 ET
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
2022-04-06 12:00 ET
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
2022-03-08 21:35 ET
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
2022-03-08 21:35 ET
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
2022-02-28 21:36 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
2022-02-28 21:36 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
2022-02-03 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2022-02-03 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2022-01-25 21:30 ET
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
2022-01-25 21:30 ET
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
2021-12-10 13:00 ET
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
2021-12-10 13:00 ET
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
2021-12-06 11:42 ET
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
2021-12-06 11:42 ET
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
2021-12-02 13:00 ET
Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
2021-12-02 13:00 ET
Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
2021-11-10 13:00 ET
Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
2021-11-10 13:00 ET
Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
2021-11-05 01:01 ET
Merus Announces Pricing of Public Offering of Common Shares
2021-11-05 01:01 ET
Merus Announces Pricing of Public Offering of Common Shares
2021-11-04 20:07 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2021-11-04 20:07 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2021-11-02 20:20 ET
Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update
2021-11-02 20:20 ET
Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update
2021-10-07 13:00 ET
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
2021-10-07 13:00 ET
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
2021-09-30 20:35 ET
Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
2021-09-30 20:35 ET
Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
2021-09-07 12:00 ET
Merus to Participate in Upcoming Investor Conferences
2021-09-07 12:00 ET
Merus to Participate in Upcoming Investor Conferences
2021-08-05 21:00 ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
2021-08-05 21:00 ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
2021-07-21 12:00 ET
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
2021-07-21 12:00 ET
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
2021-07-07 20:20 ET
Merus to Participate in William Blair's Biotech Focus Conference 2021
2021-07-07 20:20 ET
Merus to Participate in William Blair's Biotech Focus Conference 2021
2021-06-04 16:00 ET
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
2021-06-04 16:00 ET
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
2021-05-26 20:01 ET
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
2021-05-26 20:01 ET
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
2021-05-19 21:01 ET
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
2021-05-19 21:01 ET
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
2021-05-13 12:00 ET
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
2021-05-13 12:00 ET
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
2021-05-11 12:00 ET
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
2021-05-11 12:00 ET
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
2021-05-06 21:14 ET
Merus Announces Financial Results for the First Quarter and Provides Business Update
2021-05-06 21:14 ET
Merus Announces Financial Results for the First Quarter and Provides Business Update
2021-05-03 20:01 ET
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
2021-05-03 20:01 ET
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
2021-04-28 20:01 ET
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
2021-04-28 20:01 ET
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
2021-03-16 20:57 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
2021-03-16 20:57 ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
2021-03-10 21:45 ET
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
2021-03-10 21:45 ET
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
2021-03-08 13:00 ET
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
2021-03-08 13:00 ET
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
2021-02-01 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2021-02-01 13:00 ET
Merus to Participate in Upcoming Investor Conferences
2021-01-21 13:40 ET
Merus Announces Pricing of Public Offering of Common Shares
2021-01-21 13:40 ET
Merus Announces Pricing of Public Offering of Common Shares
2021-01-19 21:18 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2021-01-19 21:18 ET
Merus N.V. Announces Proposed Public Offering of Common Shares
2021-01-19 11:30 ET
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
2021-01-12 21:01 ET
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
2021-01-12 21:01 ET
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
2021-01-12 17:47 ET
Merus annonce la présentation des données cliniques de phase 1 sur le MCLA-158 lors du Symposium sur les cancers gastro-intestinaux 2021 de l'American Society of Clinical Oncology (ASCO)
2021-01-11 22:10 ET
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
2021-01-11 22:10 ET
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
2021-01-07 21:05 ET
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
2021-01-07 21:05 ET
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
2020-12-17 13:00 ET
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
2020-12-17 13:00 ET
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
2020-11-16 13:00 ET
Merus to Present at the Jefferies Virtual London Healthcare Conference
2020-11-16 13:00 ET
Merus to Present at the Jefferies Virtual London Healthcare Conference
2020-11-09 13:00 ET
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
2020-11-09 13:00 ET
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
2020-11-05 21:10 ET
Merus Announces Financial Results for the Third Quarter and Provides Business Update
2020-11-05 21:10 ET
Merus Announces Financial Results for the Third Quarter and Provides Business Update
2020-10-12 21:00 ET
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
2020-10-12 21:00 ET
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
2020-08-07 12:30 ET
Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
2020-08-06 20:07 ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
2020-07-27 12:00 ET
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
2020-07-27 12:00 ET
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
2020-07-13 20:01 ET
Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients
2019-04-03 20:00 ET
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
2019-04-01 11:00 ET
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
2019-03-11 08:09 ET
Merus to Present at the Cowen & Co. 39th Annual Health Care Conference
2019-02-07 12:00 ET
Merus to Participate in Guggenheim Healthcare Talks Idea Forum
2019-01-07 12:00 ET
Merus Announces IND Clearance for MCLA-145

SEC forms

Show financial reports only

SEC form 10
2025-08-05 20:01 ET
Merus reported for 2025 q2
SEC form 8
2025-06-04 21:36 ET
Merus published news for 2025 q1
SEC form 8
2025-06-04 21:36 ET
Merus published news for 2025 q1
SEC form 8
2025-06-04 21:36 ET
Merus published news for 2025 q1
SEC form 10
2025-05-07 20:05 ET
Merus reported for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Merus published news for 2013 q4
SEC form 10
2025-05-07 00:00 ET
Merus reported for 2025 q1
SEC form 10
2025-02-27 21:05 ET
Merus published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Merus reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Merus published news for 2013 q4
SEC form 10
2024-10-31 08:00 ET
Merus reported for 2024 q3
SEC form 10
2024-08-01 16:05 ET
Merus published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Merus reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Merus reported for 2024 q1
SEC form 10
2024-02-28 16:05 ET
Merus reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Merus published news for 2023 q4
SEC form 10
2023-11-02 16:05 ET
Merus reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Merus published news for 2023 q3
SEC form 10
2023-08-07 16:13 ET
Merus reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Merus published news for 2023 q2
SEC form 6
2023-06-15 07:30 ET
Merus published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Merus reported for 2023 q1
SEC form 10
2023-02-28 16:09 ET
Merus reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Merus published news for 2022 q4
SEC form 6
2023-01-09 06:10 ET
Merus published news for 2022 q4
SEC form 6
2023-01-06 08:00 ET
Merus published news for 2022 q4
SEC form 10
2022-11-03 07:31 ET
Merus reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Merus reported for 2022 q3
SEC form 10
2022-08-08 16:08 ET
Merus reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
Merus reported for 2022 q2
SEC form 6
2022-05-31 17:14 ET
Merus published news for 2022 q1
SEC form 10
2022-05-09 16:06 ET
Merus reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Merus reported for 2022 q1
SEC form 6
2022-04-29 08:15 ET
Merus published news for 2022 q1
SEC form 6
2022-04-19 06:05 ET
Merus published news for 2022 q1
SEC form 10
2022-02-28 16:15 ET
Merus published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Merus published news for 2021 q4
SEC form 6
2022-01-25 16:42 ET
Merus published news for 2021 q4
SEC form 6
2021-11-08 17:25 ET
Merus published news for 2021 q3
SEC form 10
2021-11-02 16:06 ET
Merus published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Merus published news for 2021 q3
SEC form 10
2021-08-05 16:09 ET
Merus published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Merus published news for 2021 q2
SEC form 6
2021-06-02 16:05 ET
Merus published news for 2021 q1
SEC form 6
2021-05-28 17:27 ET
Merus published news for 2021 q1
SEC form 6
2021-05-06 19:00 ET
Merus published news for 2021 q1
SEC form 10
2021-05-06 16:01 ET
Merus published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Merus published news for 2021 q1
SEC form 6
2021-04-29 07:07 ET
Merus published news for 2021 q1
SEC form 6
2021-04-19 07:00 ET
Merus published news for 2021 q1
SEC form 6
2021-03-29 16:00 ET
Merus published news for 2020 q4
SEC form 10
2021-03-16 16:22 ET
Merus published news for 2020 q4
SEC form 6
2021-01-22 16:04 ET
Merus published news for 2020 q4
SEC form 6
2021-01-20 17:24 ET
Merus published news for 2020 q4
SEC form 6
2021-01-19 07:57 ET
Merus published news for 2020 q4
SEC form 10
2020-11-05 16:00 ET
Merus published news for 2020 q3